Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
This biotech company, which focuses on the R&D of stem cell drugs, has filed for listing on the Hong Kong Stock Exchange, hoping to get a slice from the hot…
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK - Health Guard plans dual listing to fund HPV vaccine fight
-
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
- CHINA BULLETIN: Factories Send Mixed Signals
- CHINA BULLETIN: Services, Trade Send Positive Signals
-
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
1548.HK LEGN.US
